ABCL Stock — Price, Charts & Analysis

AbCellera Biologics Inc. (ABCL) has no trailing P/E shown and a forward P/E of -16.29x. This places ABCL in not enough valuation data territory based on the valuation data currently available on Worldtickers.

ABCL trades with -16.29x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether ABCL looks overvalued or undervalued.

ABCL's P/E of -16.29x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

ABCL's trailing EPS is -$0.58 and forward EPS is -$0.72.

EPS, or earnings per share, shows how much profit AbCellera Biologics Inc. generated for each share. ABCL's trailing EPS is -$0.58, and investors usually prefer EPS that is positive and growing over time.

AbCellera Biologics Inc. has a market cap of $3.77B, making ABCL a mid-cap stock based on the current market value shown on Worldtickers.

ABCL's latest stock price on Worldtickers is $11.65. The latest move is -$0.36 or -3.04%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

ABCL's quote includes a latest price of $11.65. The market open is $11.74. Previous close is $12.01. The intraday range is $11.59 to $12.08.

ABCL is down in the latest quote, with a move of -$0.36 or -3.04%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

ABCL generated $66.17M in trailing revenue. Revenue growth is -76.30%, which helps show whether demand is expanding or slowing.

ABCL's revenue growth is -76.30%, which is a negative demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

No, ABCL does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -$164.66M.

Gross margin is -198.88%. Margins show how efficiently AbCellera Biologics Inc. turns revenue into profit.

AbCellera Biologics Inc. carries $135.62M and holds $540.10M in cash.

ABCL holds $540.10M on its balance sheet.

ABCL's book value per share is $2.92.

Institutions hold 36.68% of ABCL shares. Insiders hold 21.74% of shares. Ownership mix helps investors understand how much of AbCellera Biologics Inc. is held by professional investors and company insiders.

ABCL has 324.05M shares outstanding. Float shares are 209.1M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for ABCL, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for ABCL is -$0.72. Revenue growth is -76.30%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

ABCL's trailing EPS is -$0.58. Forward EPS is -$0.72. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

ABCL is in the Healthcare sector. Its earnings multiple is -16.29x. Its latest displayed growth metric is -76.30%. Compare these figures with sector peers before deciding whether AbCellera Biologics Inc. is stronger or weaker than average.

ABCL trades at $11.65. The stock trades at -16.29x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of AbCellera Biologics Inc.'s fundamentals.

ABCL risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 1.19, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

ABCL should be compared with companies in Biotechnology. Its earnings multiple is -16.29x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

AbCellera Biologics Inc. (ABCL) operates in Healthcare, specifically Biotechnology. AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and

ABCL trades on NasdaqGS. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

ABCL stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

AbCellera Biologics Inc.'s official website listed on Worldtickers is www.abcellera.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

AbCellera Biologics Inc. employs about 562 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

AbCellera Biologics Inc. is headquartered in Vancouver, BC, Canada. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

ABCL is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

ABCL has traded between $2.75 and $12.15 over the past 52 weeks. At $11.65, it is 4.16% below the high and 324.23% above the low. The 52-week range helps gauge long-term price momentum.

ABCL is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $7.09 and its 200-day moving average is $4.73.

ABCL's RSI is 78.07. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a overbought momentum setup.

ABCL's latest RSI reading is 78.07, which points to overbought momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for ABCL is near $4.98. Key resistance is near $12.15. Breaks above resistance or below support can change the short-term technical setup.

ABCL's nearest reported support level is $4.98. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

ABCL's nearest reported resistance level is $12.15. A breakout above resistance can improve momentum, especially when volume confirms the move.

ABCL trades about 8.18M shares daily on average. The latest displayed volume is 2.27M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

ABCL's MACD is 0.45, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

ABCL is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 78.07 (overbought). MACD is bullish. Nearest support is around $4.98. Resistance is around $12.15. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $8.09 (44.01% from price). MA50 is $7.09 (64.34% from price). MA200 is $4.73 (146.17% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. ABCL's MA20 is $8.09. MA50 is $7.09. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

ABCL's pivot is near $11.88. Support is near $4.98. Resistance is near $12.15. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for ABCL is near $7.27. These levels help define risk and possible follow-through zones after a breakout or breakdown.

ABCL's Bollinger range is roughly $2.88 to $13.29. Band width is near 128.71%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

ABCL's ATR-based typical daily range is about 6.96%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 2.27M shares. Average volume is about 8.18M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

ABCL's all-time high shown on Worldtickers is $71.91. Its all-time low is $1.89. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

ABCL has a beta of 1.19, meaning it has historically been more volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.